Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019
- PMID: 30841008
- DOI: 10.1055/a-0859-1883
Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019
Abstract
Patients with chronic atrophic gastritis or intestinal metaplasia (IM) are at risk for gastric adenocarcinoma. This underscores the importance of diagnosis and risk stratification for these patients. High definition endoscopy with chromoendoscopy (CE) is better than high definition white-light endoscopy alone for this purpose. Virtual CE can guide biopsies for staging atrophic and metaplastic changes and can target neoplastic lesions. Biopsies should be taken from at least two topographic sites (antrum and corpus) and labelled in two separate vials. For patients with mild to moderate atrophy restricted to the antrum there is no evidence to recommend surveillance. In patients with IM at a single location but with a family history of gastric cancer, incomplete IM, or persistent Helicobacter pylori gastritis, endoscopic surveillance with CE and guided biopsies may be considered in 3 years. Patients with advanced stages of atrophic gastritis should be followed up with a high quality endoscopy every 3 years. In patients with dysplasia, in the absence of an endoscopically defined lesion, immediate high quality endoscopic reassessment with CE is recommended. Patients with an endoscopically visible lesion harboring low or high grade dysplasia or carcinoma should undergo staging and treatment. H. pylori eradication heals nonatrophic chronic gastritis, may lead to regression of atrophic gastritis, and reduces the risk of gastric cancer in patients with these conditions, and it is recommended. H. pylori eradication is also recommended for patients with neoplasia after endoscopic therapy. In intermediate to high risk regions, identification and surveillance of patients with precancerous gastric conditions is cost-effective.
© Georg Thieme Verlag KG Stuttgart · New York.
Conflict of interest statement
M. Leja has shares in and receives a salary from the Digestive Diseases Centre GASTRO, SIA (from approximately 2000 to present); his department receives research support with a special offer for reagents (including for pepsinogen detection) from Eiken Chemical (2013 to present); he is a Board member of the Latvian Association of Gastroenterology (from approximately 2000 to present), F. Megraud’s department has received a grant from Allergan (2014 to February 2019). J. E. van Hooft has received lecture fees from Medtronic (2014 – 2015) and consultancy fees from Boston Scientific (2014 – 2016); her department has received research grants from Cook Medical (2014 – 2018) and Abbott (2014 – 2017). B. Annibale, M. Areia, R. Barros, F. Carneiro, M. Dinis-Ribeiro, J.-M. Dumonceau, G. Esposito, J.-F. Fléjou, M. Garrido, I. Kikuste, E. J. Kuipers, D. Libânio, R. Marcos-Pinto, T. Matysiak-Budnik, and P. Pimentel-Nunes have no competing interests.
Similar articles
-
Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) Guideline update 2025.Endoscopy. 2025 May;57(5):504-554. doi: 10.1055/a-2529-5025. Epub 2025 Mar 20. Endoscopy. 2025. PMID: 40112834
-
Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).Endoscopy. 2012 Jan;44(1):74-94. doi: 10.1055/s-0031-1291491. Epub 2011 Dec 23. Endoscopy. 2012. PMID: 22198778 Free PMC article.
-
AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review.Gastroenterology. 2025 Feb;168(2):405-416.e1. doi: 10.1053/j.gastro.2024.11.001. Epub 2024 Dec 23. Gastroenterology. 2025. PMID: 39718517 Review.
-
Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).Virchows Arch. 2012 Jan;460(1):19-46. doi: 10.1007/s00428-011-1177-8. Epub 2011 Dec 22. Virchows Arch. 2012. PMID: 22190006
-
[European guideline for the management of precancerous conditions in the stomach and it's application to Japan].Nihon Rinsho. 2013 Aug;71(8):1479-84. Nihon Rinsho. 2013. PMID: 23967683 Review. Japanese.
Cited by
-
Factors associated with the progression of gastric intestinal metaplasia: a multicenter, prospective cohort study.Endosc Int Open. 2021 Mar;9(3):E297-E305. doi: 10.1055/a-1314-6626. Epub 2021 Feb 18. Endosc Int Open. 2021. PMID: 33655025 Free PMC article.
-
Mortality from upper gastrointestinal tumors in colorectal cancer screening patients.Endosc Int Open. 2024 Jul 25;12(7):E916-E923. doi: 10.1055/a-2348-9264. eCollection 2024 Jul. Endosc Int Open. 2024. PMID: 39055263 Free PMC article.
-
Chemoprevention Against Gastric Cancer.Gastrointest Endosc Clin N Am. 2021 Jul;31(3):519-542. doi: 10.1016/j.giec.2021.03.006. Gastrointest Endosc Clin N Am. 2021. PMID: 34053637 Free PMC article. Review.
-
Biopsy Sampling in Upper Gastrointestinal Endoscopy: A Survey from 10 Tertiary Referral Centres Across Europe.Dig Dis. 2021;39(3):179-189. doi: 10.1159/000511867. Epub 2020 Oct 1. Dig Dis. 2021. PMID: 33002891 Free PMC article.
-
The Importance of Th2 Immune Responses in Mediating the Progression of Gastritis-Associated Metaplasia to Gastric Cancer.Cancers (Basel). 2024 Jan 25;16(3):522. doi: 10.3390/cancers16030522. Cancers (Basel). 2024. PMID: 38339273 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical